Sustained Efficacy of Secukinumab in Subjects with Moderate-to-Severe Palmoplantar Psoriasis: 2 ·5-Year Results from GESTURE, a Randomized, Double-blind, Placebo-controlled Trial.

CONCLUSIONS: GESTURE, the largest and longest duration randomized controlled trial in ppPsO to date, revealed that secukinumab provides a strong and sustained response over 2·5 years in challenging-to-treat ppPsO. This article is protected by copyright. All rights reserved. PMID: 31286480 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research

Related Links:

ConclusionThe safety profile of adalimumab was consistent with previous findings and no new safety signals were observed.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
AbstractDespite a ballooning therapeutic tool box, treatment responses to newer biologic agents and oral small molecules in psoriatic arthritis (PsA) and spondyloarthritis (SpA) are of similar magnitude to those observed with anti ‐Tumor Necrosis Factor (TNF) medications (1, 2).The PsA and SpA therapeutic outcomes stand in marked contrast to those reported in psoriasis where blockade of molecules in the IL‐23/IL‐17 pathway often provide prolonged, deep responses and in some cases even remission (3). The underlying mecha nisms that account for these divergent outcomes in the skin and joint are not well understood and ...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Editorial Source Type: research
Publication date: Available online 15 November 2019Source: Autoimmunity ReviewsAuthor(s): José María G. Ruiz de Morales, Lluís Puig, Esteban Daudén, Juan D. Cañete, José Luis Pablos, Antonio Olveira Martín, Carlos González Juanatey, Alfredo Adán, Xavier Montalbán, Natalia Borruel, Guillermo Ortí, Esther Holgado Martín, Carolina García-Vidal, Cynthia Vizcaya Morales, Víctor Martín Vázquez, Miguel Ángel González-GayAbstractInterleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of...
Source: Autoimmunity Reviews - Category: Allergy & Immunology Source Type: research
In conclusion, the PEST-bp questionnaire proved to be suitable as a screening tool for PsA in patients with psoriasis. Elevated PEST-bp scores are associated with decreased patient quality of life.
Source: Archives of Dermatological Research - Category: Dermatology Source Type: research
TUESDAY, Nov. 12, 2019 -- For patients with psoriatic arthritis (PsA), the age of psoriasis onset determines whether arthritis or psoriasis starts first, according to a study presented at the annual meeting of the American College of Rheumatology,...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news
ConclusionsSecukinumab appears to be cost effective compared with other DMARDs for the treatment of active PsA in biologic-na ïve and biologic-experienced populations in Germany.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
Authors: Bakewell C, Aydin SZ, Ranganath VK, Eder L, Kaeley GS Abstract Psoriatic arthritis (PsA) affects up to 30% of patients with psoriasis and may include musculoskeletal manifestations such as enthesitis. Enthesitis is associated with joint damage, and early detection and treatment are essential to management of the disease. Traditionally assessed by clinical examination and conventional radiography, entheseal inflammation can now be more accurately assessed earlier in the disease using techniques such as ultrasound, magnetic resonance imaging, computed tomography, and molecular imaging. However, there is litt...
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
Authors: Haddad A, Feld J, Zisman D Abstract Several screening questionnaires have been developed to identify patients with psoriatic arthritis (PsA) in the psoriasis population in dermatology and general practice settings1,2,3,4,5 However, the diagnosis of PsA using these questionnaires is a topic for debate, partly because of disease heterogeneity, and the complications from inconsistent performance results6,7,8,9. PMID: 31676694 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
It is impossible to know who will develop psoriatic arthritis, though it usually affects people who already have psoriasis. Learn about whether people can prevent psoriatic arthritis here.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news
Interleukin-17 mediates immunity against pathogens such as Candida. Ixekizumab, an anti-interleukin-17A antibody, showed efficacy treating psoriasis (PsO) and psoriatic arthritis (PsA). Detailed here are Candida infections from 11 PsO and three PsA ixekizumab studies. Overall, patients received 80-mg ixekizumab every 2 or 4 weeks for 12 weeks (PsO) or 24 weeks (PsA) and then every 4 weeks. Candida (high-level term), six Candida subcategories (oral, vulvovaginal, skin, esophageal, nail, and unspecific), and four fungal infections (esophagitis, oral, oropharyngitis, and vulvovaginal mycotic) were included. Patients were cou...
Source: JDNA: Journal of the Dermatology Nurses Association - Category: Dermatology Tags: FEATURE ARTICLES Source Type: research
More News: Arthritis | Dermatology | Psoriasis | Psoriatic Arthritis | Rheumatology | Skin | Study | UK Health